NAD+ Pre-Filled Syringes Recalled for Lack of Sterility Assurance
Thrive Health Solutions is recalling NAD+ 100mg/mL pre-filled syringes (Lot #O-O8A01-25) distributed nationwide due to lack of assurance of sterility. Consumers should not use this product.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class II recall. Lack of sterility assurance in injectable products poses a significant risk of serious adverse health consequences, including infection, even though no reported illnesses are mentioned in the source text.
Plain-English summary
Thrive Health and Wellness, LLC, dba Thrive Health Solutions, is recalling NAD+ 100mg/mL pre-filled syringes due to lack of assurance of sterility. The affected product is a 16-syringe package with Lot #O-O8A01-25 and expiration date 3/7/2025, manufactured by Thrive Health Solutions located at 88 Inverness Circle East, Suite A-204, Englewood, Colorado 80112.
The product was distributed nationwide in the United States. Consumers who have purchased this product should not use it and should contact Thrive Health Solutions or consult their healthcare provider for guidance on next steps.
The recalled product
- Product
- Nicotinamide adenine dinucleotide (NAD+): 100mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
- Affected units
- 16
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: O-O8A01-25
- Exp 3/7/2025
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same manufacturer · Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
See all →- SevereLX Bioboost Plus Pre-filled Syringe Recalled for Sterility Assurance
FDA (Drugs) · 2025-07-02
- SevereLL Bioboost Injectable pre-filled syringes recalled for lack of sterility assurance
FDA (Drugs) · 2025-07-02
- ModerateTirzepatide Injections Pre-filled Syringe Recalled for Sterility Assurance
FDA (Drugs) · 2025-07-02
- SevereTirzepatide Injections recalled due to lack of sterility assurance
FDA (Drugs) · 2025-07-02
- SevereSemaglutide/Cyanocobalamin Injectable Syringes Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2025-07-02
Same hazard · lack of sterility assurance
See all →- HighPHENYLephrine HCl Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-04-03
- HighHydromorphone Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-04-03
- HighFentanyl Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighFentanyl and Bupivacaine Injectable Syringes Recalled for Sterility Defect
FDA (Drugs) · 2023-10-11
- HighSterile Eye Drops Recalled for Lack of Sterility Assurance TRP Natural Eyes
FDA (Drugs) · 2023-09-27
Similar recalls
- HighNAD+ Injectable Vials Recalled for Sterility Assurance Deficiency
FDA (Drugs) · 2023-08-30
- HighNAD+ Injectable Vials Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2022-07-20
- HighNAD+ injection recalled across all lots for lack of sterility assurance
FDA (Drugs) · 2025-10-15
- SevereApothecary NAD+ Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-10-14
- HighFDA recalls NAD+ pharmaceutical powder vials due to sterility concerns
FDA (Drugs) · 2022-06-01
- SevereAdvanced Physician Solutions Recalls Nanpyridoxine Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-06-03